Global Synthetic Lethality-based Drugs and Targets Market Size, Status and Forecast 2021-2027

In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.

Market Analysis and Insights: Global Synthetic Lethality-based Drugs and Targets Market
The global Synthetic Lethality-based Drugs and Targets market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Synthetic Lethality-based Drugs and Targets market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Synthetic Lethality-based Drugs and Targets market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Synthetic Lethality-based Drugs and Targets market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Synthetic Lethality-based Drugs and Targets market.

Global Synthetic Lethality-based Drugs and Targets Scope and Market Size
Synthetic Lethality-based Drugs and Targets market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Synthetic Lethality-based Drugs and Targets market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monotherapy
Combination Therapy

Segment by Application
Medical Research Institution
Hospital and Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Clovis Oncology
GlaxoSmithKline

Frequently Asked Questions